StockData

Rafael vs SciSparc

RFL and SPRC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RFL and SPRC compare

Rafael grew revenue faster over the last twelve months (−4.7% versus −34.5% for SciSparc).

SciSparc keeps more of each dollar of sales as profit, with a net margin of −1423% compared with −3391% at Rafael.

Rafael scores higher on the StockData Score (5 against 3 for SciSparc), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRFLSPRC
Size and price
Market cap$56.9M–
Share price$1.09$0.398
Change, 1 year−16.2%−98.4%
Change, 5 years−82.0%−100.0%
Beta (5Y)0.840.33
Employees173
StockData Score
Total score5 (better)3
Valuation score1 (better)0
Growth score11
Performance score2 (better)0
Health score12 (better)
Dividend score00
Valuation
P/S65.1×–
P/B0.9×–
FCF yield−52.7%–
Growth
Revenue growth (TTM)−4.7% (better)−34.5%
Revenue growth, 5Y average1.7%–
EPS growth (TTM)–−51.9%
EPS growth, 5Y average–36.4%
Profitability
Gross margin–73.7%
Operating margin−3823%−978% (better)
Net margin−3391%−1423% (better)
FCF margin−3431%–
Return on equity−36.9% (better)−770%
Return on invested capital−61.5%–
Financial health
Debt / equity–0.09
Interest coverage−100.3×−1.0× (better)
Current ratio2.35 (better)0.87
Altman Z-score−2.44–
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions7.5%–
Held by insiders39.2%15.6%
Insider net buying, 12 months–−$4.6K
Short interest, % of float0.92%22.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.